Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06989775

BoxX-NoAF Clinical Trial

Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hamilton General Hospital, Hamilton, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Planned and clinically indicated for cardiac surgical procedure requiring cardiac bypass and opening of the pericardium
  • Age ≥ 65 years and CHA2DS2-VASc ≥ 3

Exclusion criteria

  • Documented history of atrial fibrillation or atrial flutter anytime prior to the cardiac surgery
  • Prior procedure involving opening the pericardium or entering the pericardial space
  • Patients undergoing off-pump surgery
  • Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
  • Presence of a permanent pacemaker
  • Infiltrative cardiomyopathies (i.e. amyloidosis)
  • Planned cardiac surgical procedure using non-sternotomy approaches
  • Patients whose planned procedure is a heart transplant or implantation of any long-term ventricular assist devices
  • Presence of ventricular arrhythmia
  • Active endocarditis
  • NYHA Class IV heart failure symptoms
  • Preoperative need for an intra-aortic ballon pump or intravenous inotropes
  • Active systemic infection at the time of cardiac surgery requiring antibiotics
  • Known allergy to Nitinol or nickel sensitivity
  • Known medical condition with expected survival of less than 1 year
  • Other comorbidities that in the Investigator's opinion make the subject unsuitable candidate to complete the protocol required intervention or visits
  • Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial
  • Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial.
  • Pregnancy
  • Known severe symptomatic carotid disease

Treatment and study plan

Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System

Device

Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery

Primary outcomes

  1. Primary Effectiveness Endpoint

    Time frame: 30 days post index cardiac surgical procedure

    The occurrence of clinically relevant post operative AF (POAF)

  2. Primary Safety Endpoint

    Time frame: 30 days post index cardiac surgical procedure

    The composite of the following events:

    • All cause Mortality
    • Reoperation
    • Deep sternal wound infection
    • Permanent stroke
    • Prolonged ventilation
    • Renal failure
    • 30-day readmission
    • Atypical left atrial flutter
    • Phrenic nerve palsy
    • Major Bleeding

Secondary outcomes

  1. Powered Secondary Effectiveness Endpoint

    Time frame: 3 years post index cardiac surgical procedure

    The time to first occurrence of clinical atrial fibrillation from 30 days after index cardiac surgical procedure through 3-years

Study contacts

Contact information is provided by the study sponsor or research team.

BoxX-NoAF Trial Inbox

CONTACT

[email protected]

1 (513) 755-4100

Sponsors and collaborators

Lead sponsor

AtriCure, Inc.

Industry

Registry information

Official study title

EnCompass Clamp and the AtriClip in Box Lesion and Left Atrial Appendage EXclusion Procedure for the Prevention of New Onset of Atrial Fibrillation

Important dates

Study start
2025
Primary completion
2027
Study completion
2029
First posted
May 25, 2025
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.